1682 related articles for article (PubMed ID: 23866178)
21. A new generation of biodegradable polymer-coated sirolimus-eluting stents for the treatment of coronary artery disease: final 5-year clinical outcomes from the CREATE study.
Han YL; Zhang L; Yang LX; Liu HL; Qu P; Li WM; Jiang TM; Li SM; Jing QM; Zhang QY; Xu B; Li Y; Gao RL
EuroIntervention; 2012 Nov; 8(7):815-22. PubMed ID: 23171802
[TBL] [Abstract][Full Text] [Related]
22. First generation versus second generation drug-eluting stents for the treatment of bifurcations: 5-year follow-up of the LEADERS all-comers randomized trial.
Grundeken MJ; Wykrzykowska JJ; Ishibashi Y; Garg S; de Vries T; Garcia-Garcia HM; Onuma Y; de Winter RJ; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Corti R; Wijns W; Morice MC; di Mario C; Meier B; Jüni P; Yazdani A; Copt S; Windecker S; Serruys PW
Catheter Cardiovasc Interv; 2016 Jun; 87(7):E248-60. PubMed ID: 26649651
[TBL] [Abstract][Full Text] [Related]
23. Second-versus first-generation "Limus"-eluting stents in diabetic patients with coronary artery disease: a randomized comparison in setting of ISAR-TEST-4 trial.
Kufner S; Byrne RA; Mehilli J; Massberg S; Birkmeier KA; Schulz S; Pache J; Schömig A; Kastrati A
Catheter Cardiovasc Interv; 2013 Nov; 82(6):E769-76. PubMed ID: 23754254
[TBL] [Abstract][Full Text] [Related]
24. Sirolimus-eluting stent implantation for ostial left anterior descending coronary artery lesions: three-year outcome from the j-Cypher Registry.
Kishi K; Kimura T; Morimoto T; Namura M; Muramatsu T; Nishikawa H; Hiasa Y; Isshiki T; Nobuyoshi M; Mitsudo K;
Circ Cardiovasc Interv; 2011 Aug; 4(4):362-70. PubMed ID: 21712527
[TBL] [Abstract][Full Text] [Related]
25. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.
Mehilli J; Kastrati A; Byrne RA; Bruskina O; Iijima R; Schulz S; Pache J; Seyfarth M; Massberg S; Laugwitz KL; Dirschinger J; Schömig A;
J Am Coll Cardiol; 2009 May; 53(19):1760-8. PubMed ID: 19422982
[TBL] [Abstract][Full Text] [Related]
26. Clinical outcome after percutaneous treatment of de novo coronary bifurcation lesions using first or second generation of drug-eluting stents.
Ferenc M; Buettner HJ; Gick M; Comberg T; Rothe J; Khoury F; Valina C; Toma A; Kuebler P; Riede F; Neumann FJ
Clin Res Cardiol; 2016 Mar; 105(3):230-8. PubMed ID: 26329585
[TBL] [Abstract][Full Text] [Related]
27. Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials.
Cassese S; Kufner S; Xhepa E; Byrne RA; Kreutzer J; Ibrahim T; Tiroch K; Valgimigli M; Tölg R; Fusaro M; Schunkert H; Laugwitz KL; Mehilli J; Kastrati A
Clin Res Cardiol; 2016 Jul; 105(7):575-84. PubMed ID: 26689707
[TBL] [Abstract][Full Text] [Related]
28. Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus insight from the 4-year results of the create study.
Li Y; Han Y; Zhang L; Jing Q; Wang X; Yan G; Ma Y; Wang G; Wang S; Chen X; Yang L; Zhu G; Liu H; Jiang T
Catheter Cardiovasc Interv; 2013 Jun; 81(7):1127-33. PubMed ID: 22945767
[TBL] [Abstract][Full Text] [Related]
29. Multicenter international registry of unprotected left main coronary artery percutaneous coronary intervention with drug-eluting stents in patients with myocardial infarction.
Lee MS; Sillano D; Latib A; Chieffo A; Zoccai GB; Bhatia R; Sheiban I; Colombo A; Tobis J
Catheter Cardiovasc Interv; 2009 Jan; 73(1):15-21. PubMed ID: 19089930
[TBL] [Abstract][Full Text] [Related]
30. A randomized comparison of novel biodegradable polymer- and durable polymer-coated cobalt-chromium sirolimus-eluting stents.
Han Y; Xu B; Jing Q; Lu S; Yang L; Xu K; Li Y; Li J; Guan C; Kirtane AJ; Yang Y;
JACC Cardiovasc Interv; 2014 Dec; 7(12):1352-60. PubMed ID: 25440887
[TBL] [Abstract][Full Text] [Related]
31. Long-term clinical outcomes of sirolimus- versus paclitaxel-eluting stents for patients with unprotected left main coronary artery disease: analysis of the MAIN-COMPARE (revascularization for unprotected left main coronary artery stenosis: comparison of percutaneous coronary angioplasty versus surgical revascularization) registry.
Lee JY; Park DW; Yun SC; Lee SW; Kim YH; Lee CW; Hong MK; Park SW; Park SJ
J Am Coll Cardiol; 2009 Aug; 54(9):853-9. PubMed ID: 19695467
[TBL] [Abstract][Full Text] [Related]
32. Paclitaxel- and sirolimus-eluting stents in older patients with diabetes mellitus: results of a real-life multicenter registry.
Buja P; Facchin M; Musumeci G; Frigo AC; Saia F; Menozzi A; Meliga E; Sardella G; Tamburino C; Tarantini G
Catheter Cardiovasc Interv; 2013 Jun; 81(7):1117-24. PubMed ID: 22936398
[TBL] [Abstract][Full Text] [Related]
33. Clinical outcomes after treating acute coronary syndrome patients with a drug-eluting stent: results from REWARDS-EMI (Endeavor for Myocardial Infarction Registry).
Dvir D; Barbash IM; Torguson R; Badr S; Sardi GL; Laynez-Carnicero A; Ben-Dor I; Satler LF; Pichard AD; Waksman R
Cardiovasc Revasc Med; 2013; 14(3):128-33. PubMed ID: 23642502
[TBL] [Abstract][Full Text] [Related]
34. Impact of drug-eluting stent selection on long-term clinical outcomes in patients treated for unprotected left main coronary artery disease: the sirolimus vs paclitaxel drug-eluting stent for left main registry (SP-DELFT).
Meliga E; Garcia-Garcia HM; Valgimigli M; Chieffo A; Biondi-Zoccai G; Maree AO; Gonzalo N; Cook S; Marra S; Moretti C; De Servi S; Palacios IF; Windecker S; van Domburg R; Colombo A; Sheiban I; Serruys PW
Int J Cardiol; 2009 Sep; 137(1):16-21. PubMed ID: 18687481
[TBL] [Abstract][Full Text] [Related]
35. Multicenter international registry of unprotected left main coronary artery percutaneous coronary intervention with everolimus-eluting stents.
Lee MS; Park KW; Kang SH; Sheiban I; Mahmud E; Thani KB; Cheng R; Cho JH; Jin DK; Gwon HC; Chae IH; Aragon J; Gillis K; Stone GW; Kim HS
J Invasive Cardiol; 2012 Jul; 24(7):316-9. PubMed ID: 22781468
[TBL] [Abstract][Full Text] [Related]
36. Single-stent crossover technique from distal unprotected left main coronary artery to the left circumflex artery.
Naganuma T; Chieffo A; Basavarajaiah S; Takagi K; Costopoulos C; Latib A; Carlino M; Montorfano M; Bernelli C; Nakamura S; Colombo A
Catheter Cardiovasc Interv; 2013 Nov; 82(5):757-64. PubMed ID: 23674385
[TBL] [Abstract][Full Text] [Related]
37. Comparison of 2-year clinical outcomes between zotarolimus-, sirolimus-, and paclitaxel-eluting stents in real life clinical practice.
Kim JH; Park KW; Lim WH; Shin DH; Chae IH; Choi DJ; Kim HS
Catheter Cardiovasc Interv; 2014 Feb; 83(3):349-59. PubMed ID: 24654284
[TBL] [Abstract][Full Text] [Related]
38. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ;
JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063
[TBL] [Abstract][Full Text] [Related]
39. Sirolimus-eluting stent versus bare metal stent in diabetic patients: the final five-year follow-up of the DIABETES trial.
Jiménez-Quevedo P; Hernando L; Gómez-Hospital JA; Iñiguez A; SanRoman A; Alfonso F; Hernández-Antolín R; Angiolillo DJ; Bañuelos C; Escaned J; Gonzalo N; Fernández C; Macaya C; Sabaté M;
EuroIntervention; 2013 Jul; 9(3):328-35. PubMed ID: 23518240
[TBL] [Abstract][Full Text] [Related]
40. Incidence, time course and predictors of early vs. late target lesion revascularisation after everolimus-eluting stent implantation: a SPIRIT V substudy.
Niccoli G; Stuteville M; Sudhir K; Li D; Montone RA; Bolognese L; Grube E
EuroIntervention; 2013 Jul; 9(3):353-9. PubMed ID: 23482242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
